Man looking up
Woman looking up
Woman looking up

Itch Relief

Significant and sustained improvement in the severity of itch at nearly all timepoints measured

~68% of patients achieved WI-NRS Success at Week 8*1,3

ZORYVE(n=218)Vehicle(n=115)WEEK 2WEEK 4WEEK 8DERMIS-135%49%†67%†19%23%26%
ZORYVE(n=229)Vehicle(n=116)WEEK 2WEEK 4WEEK 8DERMIS-242%‡56%†69%†21%22%33%
†P<0.0001 vs vehicle.‡P<0.001 vs vehicle.ZORYVE(n=218)Vehicle(n=115)ZORYVE(n=229)Vehicle(n=116)WEEK 2WEEK 4WEEK 8WEEK 2WEEK 4WEEK 8DERMIS-1DERMIS-235%49%†67%†42%‡56%†69%†19%23%26%21%22%33%

†P<0.0001 vs vehicle.
‡P<0.001 vs vehicle.

*WI-NRS Success defined as a ≥4-point improvement for patients with a baseline score ≥4.
WI-NRS scale: 0 (no itch) to 10 (worst imaginable itch).

More than 2 out of 3 patients achieved a ≥4-point improvement in itch at Week 8

Did you know?Did you know?

ITCH IS THE MOST BOTHERSOME and frequently reported symptom of psoriasis, according to a 2012 population-based survey of over 2,700 patients with plaque psoriasis in North America and Europe.4

Study Design
See Before & After
View Safety Profile